Analyzing In Vivo Approaches, Delivery & Safety to Uncover their Future Potential

Time: 3:10 pm
day: Day One

Details:

  • Exploring the therapeutic potential of in vivo approaches, including in vivo and B-cell depletion to anticipate a future developments
  • Assessing if the rules that govern cancer therapies are applicable to autoimmunity to effectively evaluate knockout strategies with lentiviral vectors or opportunities for redosing with mRNA
  • Debating safety versus efficacy in the context of LNP and LVV delivery, shifting FDA perspectives, and manufacturing challenges to understand the impact on commercial outcome

Speakers:

Hussein Al-Mossawi Dr. Hussein Al-Mossawi, Vice President of Immunology Research at Immunocore, leads the development of T cell receptor-based immunotherapies for autoimmune and inflammatory diseases. A clinician Read more
Bin Wu
Tayo Sanders Dr. Tayo Sanders II is Chief Business Officer at Singular Immune, where he leads strategic partnerships and business development for in vivo cell engineering therapies. Read more
Gregory Frost